🔗 Permalink

Inventor profile of:

John BURNIER

City:

Pacifica, California

Country:

United States

Published Applications:

Last publication date:

2025-01-09

Top Assignees for applications by John BURNIER

The entities that hold a legal rights for patent applications filed by inventor BURNIER John:

SARCODE BIOSCIENCE INC. 46 Brisbane, CA United States
SARcode Bioscience Inc. 3 Bisbane, CA United States
BIPAR SCIENCES, INC. 3 Brisbane, CA United States
SARcode Corporation 3 Brisbane, CA United States
BiPar Sciences, Inc. 2 South San Francisco, CA United States
NOVARTIS PHARMACEUTICALS CORPORATION 2 EAST HANOVER, NJ United States
SARcode Corporation 1 San Francisco, CA United States
Bausch + Lomb Ireland Limited 1 Dublin, Ireland
NOVARTIS AG 1 Basel, Switzerland
BiPar Sciences, Inc. 1 Bridgewater, NJ United States

Recent patent applications by BURNIER John

John BURNIER from Pacifica, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-01-09

US20250011308A1

Chemistry; metallurgy

CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF

#2 | 2023-10-19

US20230331711A1

Chemistry; metallurgy

CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF

#3 | 2023-07-27

US20230233551A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#4 | 2022-03-10

US20220073500A1

Chemistry; metallurgy

CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF

#5 | 2021-11-04

US20210338839A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY

#6 | 2020-03-19

US20200087287A1

Chemistry; metallurgy

CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF

#7 | 2018-09-06

US20180251452A1

Chemistry; metallurgy

CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF

#8 | 2017-05-25

US20170143693A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#9 | 2017-05-25

US20170143692A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#10 | 2017-05-25

US20170143691A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#11 | 2017-05-25

US20170143690A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#12 | 2017-02-02

US20170029410A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#13 | 2016-12-22

US20160368902A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#14 | 2016-08-04

US20160220702A1

Human necessities

Compositions and methods for treatment of diabetic retinopathy

#15 | 2015-08-06

US20150218135A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#16 | 2015-08-06

US20150216857A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#17 | 2015-07-02

US20150183765A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#18 | 2015-07-02

US20150182520A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#19 | 2015-06-25

US20150175581A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#20 | 2015-06-25

US20150175580A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#21 | 2015-06-25

US20150175579A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#22 | 2015-06-25

US20150175578A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#23 | 2015-06-25

US20150175577A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#24 | 2015-06-25

US20150174119A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#25 | 2015-06-04

US20150152090A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#26 | 2015-05-21

US20150140082A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#27 | 2015-05-21

US20150140081A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#28 | 2015-05-21

US20150140080A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#29 | 2015-05-21

US20150140079A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#30 | 2015-05-21

US20150140078A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#31 | 2015-05-21

US20150140077A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#32 | 2015-05-21

US20150140076A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT

#33 | 2015-05-21

US20150140075A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#34 | 2014-12-25

US20140378506A1

Chemistry; metallurgy

Compositions and methods for treatment

#35 | 2014-12-18

US20140371265A1

Chemistry; metallurgy

Compositions and methods for treatment

#36 | 2014-06-12

US20140161872A1

Human necessities

Compositions and methods for treatment

#37 | 2014-05-22

US20140141062A1

Chemistry; metallurgy

Compositions and methods for treatment

#38 | 2014-04-10

US20140099387A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#39 | 2014-03-20

US20140079784A1

Chemistry; metallurgy

AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS

#40 | 2014-03-13

US20140073666A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATMENT

#41 | 2014-02-20

US20140051722A1

Chemistry; metallurgy

TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS

#42 | 2013-06-13

US20130150585A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#43 | 2013-06-06

US20130144063A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#44 | 2012-09-20

US20120238601A1

Chemistry; metallurgy

TREATMENT OF CANCER

#45 | 2012-09-13

US20120232019A1

Human necessities

Compositions and methods for treatment of eye disorders

#46 | 2012-05-03

US20120107404A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#47 | 2011-07-07

US20110165229A1

Human necessities

Compositions and methods for treatment

#48 | 2011-07-07

US20110165228A1

Human necessities

Compositions and methods for treatment

#49 | 2011-04-21

US20110092707A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#50 | 2010-04-15

US20100092542A1

Human necessities

Compositions and methods for treatment of eye disorders

#51 | 2010-04-15

US20100092541A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS

#52 | 2009-12-03

US20090298869A1

Chemistry; metallurgy

Crystalline pharmaceutical and methods of preparation and use thereof

#53 | 2009-11-26

US20090291924A1

Human necessities

Drug design for tubulin inhibitors, compositions, and methods of treatment thereof

#54 | 2009-10-15

US20090258070A1

Chemistry; metallurgy

Topical LFA-1 antagonists for use in localized treatment of immune related disorders

#55 | 2009-10-15

US20090258069A1

Human necessities

Delivery of LFA-1 antagonists to the gastrointestinal system

#56 | 2009-10-15

US20090257957A1

Chemistry; metallurgy

Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders

#57 | 2009-06-18

US20090155176A1

Human necessities

Compositions and methods for treatment of diabetic retinopathy

#58 | 2008-05-01

US20080103104A1

Chemistry; metallurgy

Treatment of cancer

#59 | 2008-03-27

US20080076778A1

Human necessities

METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF

#60 | 2008-03-27

US20080076737A1

Human necessities

Drug design for tubulin inhibitors, compositions, and methods of treatment thereof

#61 | 2006-12-14

US20060281739A1

Human necessities

Compositions and methods for treatment of eye disorders

InventorID:

276579 ⎘